Elfrink Willem 4
Research Summary
AI-generated summary
HeartBeam (BEAT) Director Willem Elfrink Receives Option Award
What Happened
- Willem Elfrink, a director of HeartBeam, Inc. (BEAT), was granted a derivative award on February 9, 2026 covering 51,724 shares (reported acquisition price $0.00). The grant is an option award (the "Special Option") issued under the company’s 2022 Equity Incentive Plan. This is an equity compensation grant (not an open-market purchase or sale).
Key Details
- Transaction date: February 9, 2026; Form 4 filed March 23, 2026 (filed roughly six weeks after the transaction).
- Reported consideration: $0.00 (grant of options, listed as a derivative acquisition; transaction code A = Award/Grant).
- Vesting: Half of the shares (25,862) vest on March 31, 2026; the remaining half (25,862) vest on June 30, 2026, per the filing footnote.
- Source: Options issued under the Company’s 2022 Equity Incentive Plan.
- Shares owned after transaction: not specified in the supplied filing.
- Filing timeliness: the Form 4 was submitted on March 23, 2026 covering a Feb 9 transaction, which is later than the typical 2-business-day Form 4 deadline.
Context
- This was a grant of options (equity compensation) rather than a cash purchase or sale. No exercise or sale occurred at the time of this filing. Because the options vest over time, they are not immediately fully exercisable; any future exercise or sale would produce separate filings. Equity grants to directors are common as compensation and do not by themselves indicate insider buying or selling intent.